Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.05.27.727798

Serotype-dependent bioenergetic and electrophysiological remodelling in iPSC-derived cardiomyocytes from rheumatoid arthritis patients

Abstract

BackgroundPatients with rheumatoid arthritis (RA) exhibit increased cardiovascular morbidity and mortality that are not fully explained by traditional risk factors, with cardiovascular outcomes differing between seropositive (spRA) and seronegative (snRA) disease. The cellular mechanisms linking chronic inflammation to cardiac dysfunction remain poorly defined, and no patient-specific cardiomyocyte model has resolved cellular phenotypes by RA serotype. MethodsHuman induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were generated from healthy donors and patients with spRA and snRA. Bioenergetic and electrophysiological responses to key RA proinflammatory cytokines (TNF-, IL-1{beta}, IL-6) and anti-rheumatic drugs (adalimumab, tofacitinib) were assessed using Seahorse assays, patch-clamp electrophysiology, multi-electrode array recordings and RT-qPCR. ResultssnRA cardiomyocytes exhibited impaired TNF--induced oxidative phosphorylation, accompanied by attenuated expression of ATP5B, LDHA and DLD. In contrast, spRA cardiomyocytes showed baseline electrophysiological alterations, including shortened APD90 and increased action-potential triangulation. TNF- depolarised the maximum diastolic potential in both RA serotypes. At the multicellular level, cytokine effects were serotype-specific: IL-1{beta} selectively prolonged QT interval in spRA monolayers (p < 0.001), whereas IL-6 prolonged QT in snRA (p < 0.05). Both RA serotypes showed impaired TNF--driven induction of KCNJ3 and KCNA5. Adalimumab selectively induced ATP5B in spRA but failed to engage either pathway in snRA, while tofacitinib selectively induced KCNJ3 in healthy but not RA cardiomyocytes. ConclusionsThese findings define distinct, serotype-specific pathways of cardiac remodelling in RA that converge on a shared proarrhythmic phenotype, provide a cellular framework for cardiovascular risk in RA and identify candidate mechanisms relevant to therapy-associated cardiovascular safety. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=94 SRC="FIGDIR/small/727798v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@ceb808org.highwire.dtl.DTLVardef@1942a26org.highwire.dtl.DTLVardef@5b32eforg.highwire.dtl.DTLVardef@16cf774_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wolnik, J., Adamska, P., Oleksy, A., Sanetra, A. M., Palus-Chramiec, K., Lewandowski, M. H., Dulak, J., Biniecka, M.. 2026-05-29. Serotype-dependent bioenergetic and electrophysiological remodelling in iPSC-derived cardiomyocytes from rheumatoid arthritis patients. https://doi.org/10.64898/2026.05.27.727798

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Nucleosome Core Allostery Governs Chromatin Recognition and Cell Fate

Nucleosomes regulate chromatin folding, accessibility, and factor recruitment. Current models primarily attribute these functions to histone tail modifications, while the core is largely viewed as a structural scaffold. Yet subtle changes within the nucleosome core can produce profound functional consequences, and the mechanisms underlying these effects remain unclear. Here, we describe nucleosome core allostery as a fundamental principle of chromatin regulation that amplifies the impact of minimal nucleosome variations. Leveraging natural differences between H2A.Z variants, we show that the nucleosome core encodes distinct conformational dynamics that propagate allosterically, thereby controlling nucleosome accessibility and recognition by chromatin factors. As a result, a single buried amino acid substitution alone is sufficient to reprogram nucleosome dynamics and bias cell identity. Our findings establish the nucleosome core as an allosteric regulatory module and provide a generalizable framework for how subtle variation within nucleosomes is amplified into diverse biological outcomes in development and disease.

cell biology↗

SOX4 Reprograms Adipose Stromal Cells into a Cancer-Associated Fibroblast-like State to Drive Metabolic Disease

Pathogenic adipose tissue remodeling promotes metabolic disease in obesity, but the mechanisms that establish this unhealthy tissue state remain poorly understood. Here, we show that obesity drives SOX4-dependent reprogramming of mesenchymal stromal cells (MSCs) into cancer-associated fibroblast-like (CAF-like) cells that promote adipose tissue dysfunction. TGF{beta} signaling is elevated in obesity and activates SOX4 in mouse and human MSCs, inducing their conversion to a CAF-like state. In mice, MSC-specific SOX4 activation induces the CAF-like program and exacerbates adipose tissue inflammation and glucose intolerance, whereas Sox4 deletion attenuates inflammation and improves glucose homeostasis during obesity. We further identify the growth factor Midkine (MDK) as a SOX4-regulated paracrine effector produced by CAF-like cells. MDK inhibition in obese mice reduces adipose tissue inflammation and improves metabolic function. Together, these findings define a TGF{beta}-SOX4-MDK stromal signaling axis that drives pathological adipose tissue remodeling in obesity and highlight this pathway as a potential therapeutic target for improving metabolic health.

cell biology↗

PDLIM5 Modulates YAP1 Localisation and Fibrogenic Gene Expression in Hepatic Stellate Cells

Hepatic stellate cells (HSCs) are the key cellular drivers of liver fibrosis. During liver injury and chronic inflammation HSCs adopt an activated phenotype and secrete fibrotic extracellular matrix (ECM) components such as collagen 1. Mechanical cues derived from the fibrotic ECM drive and support the activation of HSCs, via mechanisms that involve integrins and the mechano-sensitive transcriptional regulator YAP1. It is not yet well understood how external mechanical cues are translated into a molecular response that alters YAP1 nuclear shuttling. There is evidence that suggests the PDZ and LIM domain protein (PDLIM) 5 can regulate YAP1 shuttling in human epithelial cells. We therefore investigated whether PDLIM5 is expressed in HSCs and contributes to YAP1 associated HSC mechano-activation. PDLIM5 protein was detected in HSCs in fibrotic human and mouse liver. PDLIM5 transcript and protein were expressed by primary human and mouse HSCs and by the immortalised HSC LX-2 cell line. PDLIM5 localised with actin stress fibres suggesting a role in HSC adhesion. Co-immunoprecipitation and proximity ligation in LX-2 cells support an association between PDLIM5 and YAP1. We used pharmacological (paclitaxel) and genetic (siRNA and CRISPRi) approaches to inhibit PDLIM5 in HSCs. Inhibiting PDLIM5 reduced YAP1 nuclear localisation and fibrotic gene (COL1A1, ACTA2) expression in LX-2 cells. Overall, these data support a role for PDLIM5 in regulating YAP1 localisation and fibrogenic gene expression in HSCs.

cell biology↗